Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

The 1-year THALASSA study enrolled 166 patients with various non-transfusion-dependent thalassemia (NTDT) syndromes, degrees of iron burden and patient characteristics, and demonstrated the overall efficacy and safety of deferasirox in reducing liver iron concentration (LIC) in these patients. Here,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Taher, Ali T, Porter, John B, Viprakasit, Vip, Kattamis, Antonis, Chuncharunee, Suporn, Sutcharitchan, Pranee, Siritanaratkul, Noppadol, Galanello, Renzo, Karakas, Zeynep, Lawniczek, Tomasz, Habr, Dany, Ros, Jacqueline, Zhang, Yiyun, Cappellini, M Domenica
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2013
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3698696/
https://ncbi.nlm.nih.gov/pubmed/23553596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23445
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados